Ratutrelvir, a ritonavir-free Main protease (Mpro/3CL) inhibitor, was discovered and developed ab initio from target to clinic by ChemDiv's medicinal chemistry and virology services teams. Leveraging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback